Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short communication

The Coris BioConcept COVID 19 Ag Respi-Strip, a field experience feedback

Assaf Mizrahi, PharmD a,⁎, Jean-Claude Nguyen Van a, Najoua El Helali a, Julie Lourtet-Hascoet a, Ines Jabnoune a, Marie Lisse Paceau a, Yasmina Talb a, Jacques Fourgeaud c, d, Marianne Leruez-Ville c, d, Benoît Pilmis a,⁎, Véronique Avettand-Fenoel c,⁎, Alban Le Monnier b,⁎

a Service de Microbiologie clinique, Groupe hospitalier Paris Saint Joseph, Paris, France
b Institut Micalis UMR 1319, Université Paris-Saclay, INRAe, AgroParisTech, Chatenay Malabry, France
c Service de Microbiologie clinique, Hôpital Universitaire Necker - Enfants Malades, AP-HP, Paris, France
d EA7328, Université de Paris, Paris, France
e Université de Paris, CNRS 8194, INSERM U1016, Paris, France

⁎ Corresponding author at: Service de Microbiologie clinique et dosages des anti-infectieux, Groupe Hospitalier Paris Saint-Joseph, 185 rue Raymond Losserand, 75014, Paris, France.
E-mail addresses: amizrahi@ghpsj.fr, amizrahi@hpsj.fr (A. Mizrahi).

https://doi.org/10.1016/j.jviromet.2021.114366
Received 10 May 2020; Received in revised form 2 August 2021; Accepted 17 November 2021
Available online 18 November 2021
0166-0934/© 2021 Elsevier B.V. All rights reserved.

ARTICLE INFO

Keywords:
SARS-CoV-2
Antigenic test
Rapid

ABSTRACT

This communication described how the Coris BioConcept COVID-19 Ag Respi-Strip test (Coris-Ag) was implemented in the workflow of our clinical microbiology laboratory for COVID-19 diagnosis. The diagnostic performance statistics (sensitivity, specificity) of the Coris-Ag were evaluated against a gold standard, the RealStar SARS-CoV-2 RT-PCR kit 1.0. Additionally, the effect of reading the Coris-Ag results at 30 min was compared to reading at 15 min. The Coris-Ag was performed on a total of 294 patients during two periods; 158 patients were tested during period 1 at the peak of the pandemic (April 6th to April 10th 2020) which returned a positivity rate of 17.1 %, and 136 patients during period 2 (April 12th to April 16th 2020) which returned a positivity rate of 11 %. Compared to the RT-PCR, the 15-minute Coris-Ag readings resulted in a sensitivity of 59.3 % with a 100 % specificity for the period 1 patients (n = 158) while the sensitivity decreased to 20 % for the period 2 patients (n = 136). The overall sensitivity was 38.1 % for both periods (n = 294). The corresponding 30-minute readings produced a 7 % increase in sensitivity with a specificity of 100 % (n = 294). The sensitivity of the strip test (15-min reading) for high viral loads (Ct < 25) was 84.6 %.

The severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) pandemic is still on-going with a worldwide infection rate of 188,367,022 cases and 4,058,263 deaths (John Hopkins Coronavirus Resource Center, 2021). The Coris BioConcept COVID-19 Ag Respi-Strip test (Coris-Ag) is an immuno-chromatographic test that is easy to use and fast (<1 min of handling time per test followed by a 15-min incubation). For comparison, the RT-PCR assay has a time-to-result of two hours (van Kasteren et al., 2020). The Coris-Ag kit can be stored at room temperature and can be performed on the same clinical samples to be used for the RT-PCR test. According to the manufacturer’s product notes (COVID-19 Ag Respi-Strip - COVID-19 Antigen rapid test, 2021), the detection limit of Coris-Ag was determined to be 5 × 107 plaque-forming units/mL using a SARS-CoV-2 virus standard. In this context, the usefulness of the Coris-Ag was evaluated during the first peak of the COVID-19 pandemic in France (6th April 2020 to 10th April 2020).

The Coris-Ag was subjected to an initial diagnostic performance evaluation before being implemented under real-life conditions at the clinical microbiology laboratory of Groupe Hospitalier Paris Saint-Joseph, Paris, France. The initial evaluation and the real-life implementation were performed in the exact same manners except that during the initial evaluation, the results were not given to the physician. All samples tested were naso-pharyngeal swabs in Universal Transport Medium (UTM-RT, Copan, USA) from patients with clinical suspicion of COVID-19 from the Groupe Hospitalier Paris Saint-Joseph. The diagnostic performance statistics of Coris-Ag were obtained using the RealStar SARS-CoV-2 RT-PCR kit 1.0 (Altona Diagnostics GmbH, Hamburg, Germany) RT-PCR assay as the gold standard. The initial evaluation before being implemented under real-life conditions at the clinical microbiology laboratory of Groupe Hospitalier Paris Saint-Joseph, Paris, France. The initial evaluation and the real-life implementation were performed in the exact same manners except that during the initial evaluation, the results were not given to the physician. All samples tested were naso-pharyngeal swabs in Universal Transport Medium (UTM-RT, Copan, USA) from patients with clinical suspicion of COVID-19 from the Groupe Hospitalier Paris Saint-Joseph. The diagnostic performance statistics of Coris-Ag were obtained using the RealStar SARS-CoV-2 RT-PCR kit 1.0 (Altona Diagnostics GmbH, Hamburg, Germany) RT-PCR assay as the gold standard. The initial evaluation was conducted on 52 nasopharyngeal samples collected from patients and based on the 15-min reading of the Coris-Ag. When the samples arrived in the laboratory, the Coris-Ag was performed and then RT-PCR analysis...
was performed using the same sample. No changes to the supplier’s data were made for the Coris-Ag or for the RT-PCR analysis. This same workflow was used for the real-life conditions testing. The evaluation under real-life conditions was conducted on a total of 294 different patients over two periods of 1 week each. Period 1 (April 6th to April 10th 2020) was at the peak of the pandemic and 158 patients were tested. Period 2 was the following week (April 12th to April 16th 2020) with 136 patients tested.

The Coris-Ag was prospectively evaluated based on reading the test results at 15 min as recommended by the manufacturer, as well as on a second reading at 30 min. The results of the RT-PCR assays were based on cycle threshold (Ct) values, with Ct > 37 as being virus-negatives as specified by the French Society of Microbiology (“Avis du 25 septembre 2020 de la Société Française de Microbiologie (SFM) relatif à l’interprétation de la valeur de Ct (estimation de la charge virale) obtenue en cas de RT-PCR SARS-CoV-2 positive sur les prélèvements cliniques réalisés à des fins diagnostiques ou de dépistage,”, 2021). The diagnostic performance statistics of Coris-Ag were then calculated for the 15-min and 30-min readings, and for the Periods 1 and 2 patients separately. The RT-PCR virus-positive samples from the real-life screening were classified semi-quantitatively according to the ranges of cycle threshold (Ct) values as follows:

- Very high viral load (< 25 Ct)
- High viral load (25 < Ct < 30)
- Medium viral load (30 < Ct < 35)
- Low viral load (Ct > 35)
- Negative viral load (Ct > 37)

The diagnostic performance of Coris-Ag was also evaluated based on only those RT-PCR assays with a PCR Ct < 25 as being real positives.

The initial evaluation of the Coris-Ag system based on the 15-min reading on the 52 samples produced eight true positives, 0 false positives, 41 true negatives and three false negatives (Table 1, Column 2). The results based on the 52 samples produced eight true positives, 0 false positives, 41 true negative and three false negatives (Table 1, Column 2). The results of the initial evaluation were consistent with those of the two-week real-life screening of the 294 patients were calculated for the 15-min and 30-min readings, and for the Periods 1 and 2 patients separately. The RT-PCR virus-positive samples from the real-life screening were classified semi-quantitatively according to the ranges of cycle threshold (Ct) values as follows:

| Table 1 | Diagnostic performance statistics of the Coris BioConcept COVID-19 Ag Respi-Strip test compared to the RealStar SARS-CoV-2 RT-PCR kit 1.0 assay obtained from the initial evaluation of 52 samples and the two-week real-life screening of 294 samples. |
|---------|------------------------------------------------------------------------------|
| Coris-Ag | Initial evaluation (15-min reading) (n = 52) | Coris-Ag: 15-min reading (n = 294) | Coris-Ag: 30-min reading (n = 294) | Period 1 (n = 158) | Period 2 (n = 136) |
| PPV (%) | 100 | 100 | 100 | 100 |
| NPV (%) | 93.0 | 90.6 | 91.6 | 92.2 |
| Sensitivity (%) | 72.0 | 38.1 | 45.2 | 59.3 |
| Specificity (%) | 100 | 100 | 100 | 100 |
| Positive rate of RT-PCR (%) | 22.6 | 14.3 | 14.3 | 17.1 |
| Positive rate of Coris-Ag (%) | 15.4 | 5.4 | 6.5 | 10.1 |
| Coris-Ag accuracy (%) | 94.2 | 91.2 | 92.2 | 93.0 |

PPV = positive predictive value and NPV = negative predictive value.
Accuracy = (true positive + true negative)/true positive + false negative + true negative + false positive).

Table 2 | Relationship between indicative virus load (Ct values) of the PCR-positive samples and the resultant diagnostic performance of Coris-Ag.
|--------------|----------------|-----------------|----------------|
| Viral load category | Total PCR (true positive) | Positive Coris-Ag (% of Ct category) | Negative Coris-Ag (% of false negatives) |
| Very high viral load (Ct<25) | 13 | 11 (84.6) | 2 (8.7) |
| High viral load (25 ≤ Ct<30) | 14 | 8 (57.1) | 6 (26.1) |
| Medium viral load (30 ≤ Ct<35) | 8 | 0 (0) | 8 (34.8) |
| Low viral load (Ct ≥ 35) | 7 | 0 (0) | 7 (30.4) |
| Total | 42 | 19 (45.2) | 23 (100) |

Based on the 30-min readings of the 294 samples.
Positives identified by the gold standard RT-PCR assay.
Percentages were of the total number of positives in each virus load category by the gold standard RT-PCR assay.
Total number of false-negatives was 23.

The results of the initial evaluation were consistent with those of the evaluations conducted in two teaching hospitals in Belgium (Brussels and Liege) on 99 and 132 patients, respectively (COVID-19 Ag Respi-Strip - COVID-19 Antigen rapid test, 2021). Their results showed a specificity of 100 % and sensitivities of 60 % and 60.3 %, respectively.
The implementation of Coris-Ag went smoothly in the clinical microbiology laboratory. Since the PPVs of Coris-Ag were 100% (i.e., no false positives) in all the test groups in this study (Table 1), each Coris-Ag-positive result did not require RT-PCR confirmation and was reported in the patient’s medical record and communicated to the referring physician. This would allow a rapid transfer of the patient to dedicated COVID wards. In the case of a negative result, the result was not communicated to the physician nor recorded in the medical chart. In that case, a final diagnosis should be made according to the RT-PCR result.

The Coris-Ag detected only 38% (16/42) of the true positive samples, or 6% (16/294) of the patients, by the 15-min reading recommended by the manufacturer. These were mainly those with the highest viral loads. For these patients, diagnostic results were available rapidly, facilitating their early referral to the right COVID area. It should be stressed that the high sensitivity of Coris-Ag, obtained when the PCR Ct <25, is of high healthcare value since it allows a quick but reliable diagnosis of patients with very high viral loads. Indeed, COVID-19 patients with severe disease symptoms had significantly higher viral loads than those with mild disease in respiratory samples and therefore, could be diagnosed reliably and quickly using Coris-Ag instead of RT-PCR (Zheng et al., 2020). However, this study showed that the Coris-Ag test sensitivity obtained during Period 2 was unacceptably low (20%) when COVID-19 prevalence was low (11%), suggesting its limitation as a screening program outside of the pandemic peak. This phenomenon may be explained by the observation that a decrease in the number of patients with high viral loads was associated with a decrease of overall disease incidence (data not shown). Scohy et al. (2020) found a low diagnostic sensitivity of 30.2% in their Coris-Ag screening of 148 samples, and Blairon et al. (2020) reported a median sensitivity of 23.9% for Coris-Ag test, both of which are consistent with the findings of this study. Similarly, Lambert-Nicolot et al. (2020) obtained a sensitivity of 50% (47 Coris-Ag-positives on 94 PCR-positives samples) and found a corresponding increase in sensitivity with very high viral loads (Ct <25). The results of this study confirmed this trend on a larger cohort.

This study is the first that evaluated a 30-min reading time in addition to a 15-min reading time, resulting in a 7% increase (38.1%–45.2%) in sensitivity. These results indicated that extending the reading time from 15 min to 30 min could increase the sensitivity. This is encouraging but need to be confirmed by a larger cohort in order to avoid false positive.

Based on the results of this study, the Coris-Ag system should be used in some developing countries where RT-PCR may not be easily or extensively available. Another potential for this test is for it to be used directly by physicians as a doctor’s test, mostly in geriatrics long-time care in case of local clusters developing. The cost range of Coris-Ag is between 5–10 USD per test, depending on the volume ordered. This is about four to five times cheaper than a RT-PCR assay. The extra cost of the PCR assay must be taken into account and could be reduced if Coris-Ag is used for the diagnosis of patients within the first few days of the onset of clinical symptoms, for patients with severe disease and during periods when the prevalence of COVID is high. Negative results from these preliminary screening protocols should then be retested by RT-PCR as proposed by Mertens et al. (Mertens et al., 2020). Thus, despite its limitations, the Coris-Ag system could find a use in laboratories not equipped with RT-PCR or as a point-of-care doctor’s test on the condition that negative results be confirmed by RT-PCR.

Declaration of Competing Interest

The authors report no declarations of interest.

Acknowledgments

We would like to thank Professor Thierry Lambert for his valuable advice and the Doctor My-Linh Dang-Yu for English editing.

References

Avis du 25 septembre 2020 de la Société Française de Microbiologie (SFM) relatif à l’interprétation de la valeur de Ct (estimation de la charge virale) obtenue en cas de RT-PCR SARS-CoV-2 positive sur les prélèvements cliniques réalisés à des fins diagnostiques ou de dépistage, 2021. Avis du 25 septembre 2020 de la Société Française de Microbiologie (SFM) relatif à l’interprétation de la valeur de Ct (estimation de la charge virale) obtenue en cas de RT-PCR SARS-CoV-2 positive sur les prélèvements cliniques réalisés à des fins diagnostiques ou de dépistage. Société Française de Microbiologie. URL https://www.sfm-microbiologie.org/wp-content/uploads/2021/01/Avis-SFM-valeur-Ct-excre%CC%81tion-virale-_-Version-def-14012021_V4.pdf (Accessed 7.15.21).

Blairon, L., Wilmot, A., Beukinga, L., Tré-Hardy, M., 2020. Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: Experiences of a general hospital. J Clin Virol 129, 104472. https://doi.org/10.1016/j.jcv.2020.104472.

COVID-19 Ag Respi-Strip - COVID-19 Antigen rapid test. 2021. COVID-19 Ag Respi-Strip - COVID-19 Antigen Rapid Test [WWW Document]. URL https://www.corisbio.com/products/covid19/ (Accessed 7.15.21).

John Hopkins Coronavirus Resource Center, 2021. John Hopkins Coronavirus Resource Center [WWW Document]. URL https://coronavirus.jhu.edu/.

Lambert-Nicolot, S., Cuffel, A., Le Pape, S., Vauloup-Felloux, C., Morand-Joubert, L., Roque-Alonso, A.-M., Le Goff, J., Delaugerre, C., 2020. Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs. J Clin Microbiol 58. https://doi.org/10.1128/JCM.00977-20.

Mertens, P., De Vos, N., Martiny, D., Jassoy, C., Mirazimi, A., Cuypers, L., Van den Wijngaert, S., Monteil, Y., Melin, P., Stoffels, K., Yin, N., Miletto, D., Delaunoy, S., Magerin, H., Lagrou, K., Bouzet, J., Serrano, G., Wautier, M., Leclercq, T., Van Ranst, M., Vandenberg, O., LHEUB-ULB SARS-CoV-2 Working Diagnostic Group, 2020. Development and potential usefulness of the COVID-19 Ag respi-strip diagnostic assay in a pandemic context. Front. Med. (Lausanne) 7, 225. https://doi.org/10.3389/fmed.2020.00225.

Scohy, A., Anantharajah, A., Bodeux, M., Kabamba-Mukadi, B., Verroken, A., Rodriguez-Villalobos, H., 2020. Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 129, 104455. https://doi.org/10.1016/j.jcv.2020.104455.

van Kasteren, P.B., van der Veer, B., van den Brink, S., Wijngaard, M., de Jonge, J., van den Brandt, A., Molenkamp, R., Reusken, C.B.E.M., Meijer, A., 2020. Comparison of seven commercial RT-PCR diagnostic kits for COVID-19. J. Clin. Virol. 128, 104412. https://doi.org/10.1016/j.jcv.2020.104412.

Zheng, S., Fan, J., Yu, F., Feng, B., Lou, B., Zou, Q., Xie, G., Lin, S., Wang, R., Yang, X., Chen, W., Wang, Q., Zhang, D., Liu, Y., Gong, B., Ma, Z., Lu, S., Xiao, Y., Gu, Y., Zhang, J., Yao, H., Xu, K., Lu, X., Wei, G., Zhou, J., Fang, Q., Cai, H., Qiu, Y., Sheng, J., Chen, Y., Liang, T., 2020. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ 369. https://doi.org/10.1136/bmj.m1443,